Retraction: Down-regulated peroxisome proliferator-activated receptor γ(PPARγ) in lung epithelial cells promotes a PPARγ agonist-reversible proinflammatory phenotype in chronic obstructive pulmonary disease (COPD) (Journal of Biological Chemistry (2014) 289 (6383–6393) DOI: 10.1074/jbc.M113.536805);Down-regulated peroxisome proliferator-activated receptor γ (PPARγ) in lung epithelial cells promotes a PPARγ agonist-reversible proinflammatory phenotype in chronic obstructive pulmonary disease (COPD)

Journal of Biological Chemistry

Volumn 289, Issue 10, 2014, Pages 6383-6393

  Lakshmi, Sowmya P ^a,b   Reddy, Aravind T ^a,b   Zhang, Yingze ^a   Sciurba, Frank C ^a   Mallampalli, Rama K ^a,b   Duncan, Steven R ^a   Reddy, Raju C ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOLOGY;

CHRONIC OBSTRUCTIVE PULMONARY DISEASE; CIGARETTE SMOKES; LUNG EPITHELIAL CELLS; MULTIPLE PATHWAYS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR; PROINFLAMMATORY;

PULMONARY DISEASES;

CIGARETTE SMOKE; GLUCOCORTICOID RECEPTOR ALPHA; HISTONE DEACETYLASE 2; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; REACTIVE OXYGEN METABOLITE; ROSIGLITAZONE; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOWN REGULATION; EPITHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DNA INTERACTION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; UPREGULATION;

CHROMATIN HISTONE MODIFICATION; CIGARETTE SMOKE; GLUCOCORTICOID RECEPTOR; HISTONE DEACETYLASE; HUMAN BRONCHIAL EPITHELIAL CELLS; I-KAPPA-B KINASE; INFLAMMATION; NF-KAPPA B (NF-KB); OXIDATIVE STRESS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRONCHI; CELLS, CULTURED; DOWN-REGULATION; DRUG RESISTANCE; GENE KNOCKDOWN TECHNIQUES; HISTONE DEACETYLASE 2; HUMANS; LUNG; NF-KAPPA B; OLEIC ACIDS; OXIDATIVE STRESS; PPAR GAMMA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY MUCOSA; SMOKING; THIAZOLIDINEDIONES;

EID: 84896752943     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.RX118.007042     Document Type: Erratum

References (33)

1. Mannino, D. M., and Buist, A. S. (2007) Global burden of COPD: risk factors, prevalence, and future trends. Lancet 370, 765-773
2. Barnes, P. J. (2006) Corticosteroids: the drugs to beat. Eur. J. Pharmacol. 533, 2-14
3. Barnes, P. J. (2009) Histone deacetylase-2 and airway disease. Ther. Adv. Respir. Dis. 3, 235-243
4. Doyle, K., and Fitzpatrick, F. A. (2010) Redox signaling, alkylation (carbonylation) of conserved cysteines inactivates class I histone deacetylases 1, 2, and 3 and antagonizes their transcriptional repressor function. J. Biol. Chem. 285, 17417-17424
5. Ito, K., Hanazawa, T., Tomita, K., Barnes, P. J., and Adcock, I. M. (2004) Oxidative stress reduces histone deacetylase 2 activity and enhances IL-8 gene expression: role of tyrosine nitration. Biochem. Biophys. Res. Commun. 315, 240-245
6. Adenuga, D., Yao, H., March, T. H., Seagrave, J., and Rahman, I. (2009) Histone deacetylase 2 is phosphorylated, ubiquitinated, and degraded by cigarette smoke. Am. J. Respir. Cell Mol. Biol. 40, 464-473
7. Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., and Glass, C. K. (1998) The peroxisome proliferator-activated receptor is a negative regulator of macrophage activation. Nature 391, 79-82
8. Nencioni, A., Wesselborg, S., and Brossart, P. (2003) Role of peroxisome proliferator-activated receptor and its ligands in the control of immune responses. Crit. Rev. Immunol. 23, 1-13
9. Baker, P. R. S., Schopfer, F. J., Sweeney, S., and Freeman, B. A. (2004) Red cell membrane and plasma linoleic acid nitration products: synthesis, clinical identification, and quantitation. Proc. Natl. Acad. Sci. U.S.A. 101, 11577-11582
10. Baker, P. R. S., Lin, Y., Schopfer, F. J., Woodcock, S. R., Groeger, A. L., Batthyany, C., Sweeney, S., Long, M. H., Iles, K. E., Baker, L. M. S., Branchaud, B. P., Chen, Y. E., and Freeman, B. A. (2005) Fatty acid transduction of nitric oxide signaling: multiple nitrated unsaturated fatty acid derivatives exist in human blood and urine and serve as endogenous peroxisome proliferator-activated receptor ligands. J. Biol. Chem. 280, 42464-42475
11. Reddy, A. T., Lakshmi, S. P., Kleinhenz, J. M., Sutliff, R. L., Hart, C. M., and Reddy, R. C. (2012) Endothelial cell peroxisome proliferator-activated receptor reduces endotoxemic pulmonary inflammation and injury. J. Immunol. 189, 5411-5420
12. Di Stefano, A., Caramori, G., Oates, T., Capelli, A., Lusuardi, M., Gnemmi, I., Ioli, F., Chung, K. F., Donner, C. F., Barnes, P. J., and Adcock, I. M. (2002) Increased expression of nuclear factorB in bronchial biopsies from smokers and patients with COPD. Eur. Respir. J. 20, 556-563
13. Jeffery, P. K. (2004) Remodeling and inflammation of bronchi in asthma and chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 1, 176-183
14. Alkalay, I., Yaron, A., Hatzubai, A., Orian, A., Ciechanover, A., and Ben-Neriah, Y. (1995) Stimulation-dependent I-B phosphorylation marks the NFB inhibitor for degradation via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. U.S.A. 92, 10599-10603
15. Beck, I. M., Vanden Berghe, W., Vermeulen, L., Bougarne, N., Vander Cruyssen, B., Haegeman, G., and De Bosscher, K. (2008) Altered subcellular distribution of MSK1 induced by glucocorticoids contributes to NFB inhibition. EMBO J. 27, 1682-1693
16. Ito, K., Barnes, P. J., and Adcock, I. M. (2000) Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1induced histone H4 acetylation on lysines 8 and 10. Mol. Cell. Biol. 20, 6891-6903
17. Hou, Y., Moreau, F., and Chadee, K. (2012) PPARα is an E3 ligase that induces the degradation of NFκB/p65. Nat. Commun. 3, 1300
18. Pascual, G., Fong, A. L., Ogawa, S., Gamliel, A., Li, A. C., Perissi, V., Rose, D. W., Willson, T. M., Rosenfeld, M. G., and Glass, C. K. (2005) A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR. Nature 437, 759-763
19. Martín, A., Pérez-Girón, J. V., Hernanz, R., Palacios, R., Briones, A. M., Fortuño, A., Zalba, G., Salaices, M., and Alonso, M. J. (2012) Peroxisome proliferator-activated receptor activation reduces cyclooxygenase-2 expression in vascular smooth muscle cells from hypertensive rats by interfering with oxidative stress. J. Hypertens. 30, 315-326
20. Blanquicett, C., Kang, B. Y., Ritzenthaler, J. D., Jones, D. P., and Hart, C. M. (2010) Oxidative stress modulates PPARα in vascular endothelial cells. Free Radic. Biol. Med. 48, 1618-1625
21. Adams, M., Reginato, M. J., Shao, D., Lazar, M. A., and Chatterjee, V. K. (1997) Transcriptional activation by peroxisome proliferator-activated receptor is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. J. Biol. Chem. 272, 5128-5132
22. Camp, H. S., and Tafuri, S. R. (1997) Regulation of peroxisome proliferator-activated receptor activity by mitogen-activated protein kinase. J. Biol. Chem. 272, 10811-10816
23. Hu, E., Kim, J. B., Sarraf, P., and Spiegelman, B. M. (1996) Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARα. Science 274, 2100-2103
24. Camp, H. S., Tafuri, S. R., and Leff, T. (1999) c-Jun N-terminal kinase phosphorylates peroxisome proliferator-activated receptor1 and negatively regulates its transcriptional activity. Endocrinology 140, 392-397
25. Mercer, B. A., and D'Armiento, J. M. (2006) Emerging role of MAP kinase pathways as therapeutic targets in COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 1, 137-150
26. Lahiri, S., Sen, T., and Palit, G. (2009) Involvement of glucocorticoid receptor and peroxisome proliferator activated receptor in pioglitazone mediated chronic gastric ulcer healing in rats. Eur. J. Pharmacol. 609, 118-125
27. Li, J., Dai, A., Hu, R., Zhu, L., and Tan, S. (2010) Positive correlation between PPARα/PGC-1 and GCS in lungs of rats and patients with chronic obstructive pulmonary disease. Acta Biochim. Biophys. Sin. 42, 603-614
28. Lea, S., Plumb, J., Metcalfe, H., Spicer, D., Woodman, P., Fox, J. C., and Singh, D. (2013) The effect of PPAR ligands on in vitro and in vivo models of COPD. Eur. Respir. J., 10.1183/09031936.00187812
29. Sharma, R., Kaundal, R. K., and Sharma, S. S. (2009) Amelioration of pulmonary dysfunction and neutrophilic inflammation by PPARα agonist in LPS-exposed guinea pigs. Pulm. Pharmacol. Ther. 22, 183-189
30. Wang, X., Wang, Y., Zhao, X., Andersson, R., Song, Z., and Yang, D. (2009) Potential effects of peroxisome proliferator-activated receptor activator on LPS-induced lung injury in rats. Pulm. Pharmacol. Ther. 22, 318-325
31. Lee, S. Y., Kang, E. J., Hur, G. Y., Jung, K. H., Jung, H. C., Lee, S. Y., Kim, J. H., Shin, C., In, K. H., Kang, K. H., Yoo, S. H., and Shim, J. J. (2006) Peroxisome proliferator-activated receptor inhibits cigarette smoke solution-induced mucin production in human airway epithelial (NCI-H292) cells. Am. J. Physiol. Lung Cell Mol. Physiol. 291, L84-90
32. Caito, S., Yang, S. R., Kode, A., Edirisinghe, I., Rajendrasozhan, S., Phipps, R. P., and Rahman, I. (2008) Rosiglitazone and 15-deoxy-Delta12,14- prostaglandin J2, PPARα agonists, differentially regulate cigarette smoke-mediated pro-inflammatory cytokine release in monocytes/macrophages. Antioxid. Redox. Signal. 10, 253-260
33. Li, M., Pascual, G., and Glass, C. K. (2000) Peroxisome proliferator-activated receptor dependent repression of the inducible nitric oxide synthase gene. Mol. Cell. Biol. 20, 4699-4707